Dr Sake van Wageningen
Biology-Oncology, Astex Pharmaceuticals and Department of Molecular Carcinogenesis, The NKI (Netherlands Cancer Institute), Amsterdam
The aim of this project was to determine whether inhibition of ERN1, which is involved in the unfolded protein response, could synergize with MAPK pathway inhibitors to induce tumour cell death. CRISPR functional genomic screens were also performed in order to delineate the mechanisms by which ERN1 modulates sensitivity to MAPK inhibitors.
Dr Sake van Wageningen is currently Project Leader at GenDx, The Netherlands.
